Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results, Misses Expectations By $0.12 EPS

Sangamo Therapeutics (NASDAQ:SGMO) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.12), reports. Sangamo Therapeutics had a negative return on equity of 813.95% and a negative net margin of 331.28%.The company had revenue of $14.23 million during the quarter, compared to analysts’ expectations of $40.25 million.

Here are the key takeaways from Sangamo Therapeutics’ conference call:

• Rolling BLA submission is underway for ST-920 with the clinical and non-clinical modules submitted, the companion diagnostic accepted by CDRH, process validation and method validation completed, and a first commercial lot manufactured, supported by a positive mean annualized eGFR slope that the FDA said could support accelerated approval.
• Sangamo repeatedly warned the BLA completion and broader operations are contingent on securing additional funding and a Fabry commercialization partner, noting limited cash resources despite raising >$130M in 2025 and managing spend to extend runway.
• The company has transitioned into a clinical-stage neurology company—ST-503 received Fast Track designation, six sites are active in the Phase I/II STAND study, and preclinical ST-503 data were published in Science Translational Medicine; ST-506 CTA-enabling work and GLP toxicology are also progressing.
• Sangamo emphasized continued external validation of its STAC-BBB capsid platform, announcing a third neurology capsid license (with Eli Lilly) and generating non-dilutive license fees and milestone payments as part of >$130M of 2025 funding.

Sangamo Therapeutics Stock Down 4.2%

Shares of Sangamo Therapeutics stock traded down $0.01 on Monday, reaching $0.31. The company’s stock had a trading volume of 10,293,872 shares, compared to its average volume of 6,184,460. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $0.84. The firm’s fifty day simple moving average is $0.39 and its two-hundred day simple moving average is $0.48. The company has a market capitalization of $103.40 million, a price-to-earnings ratio of -0.70 and a beta of 1.33.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SGMO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Sangamo Therapeutics in a report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, February 10th. Finally, Wall Street Zen cut shares of Sangamo Therapeutics to a “strong sell” rating in a research note on Saturday, January 31st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Sangamo Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.50.

Institutional Trading of Sangamo Therapeutics

A number of large investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Sangamo Therapeutics by 23.9% during the 3rd quarter. Vanguard Group Inc. now owns 11,615,150 shares of the biopharmaceutical company’s stock worth $7,817,000 after acquiring an additional 2,240,422 shares during the last quarter. Wasatch Advisors LP raised its holdings in Sangamo Therapeutics by 17.7% in the 2nd quarter. Wasatch Advisors LP now owns 8,084,419 shares of the biopharmaceutical company’s stock worth $4,376,000 after purchasing an additional 1,215,653 shares during the period. Geode Capital Management LLC lifted its position in Sangamo Therapeutics by 17.6% during the fourth quarter. Geode Capital Management LLC now owns 3,866,026 shares of the biopharmaceutical company’s stock valued at $1,624,000 after purchasing an additional 579,550 shares in the last quarter. Two Sigma Investments LP increased its position in Sangamo Therapeutics by 182.7% in the third quarter. Two Sigma Investments LP now owns 2,479,186 shares of the biopharmaceutical company’s stock worth $1,669,000 after buying an additional 1,602,107 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Sangamo Therapeutics by 11.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,713,331 shares of the biopharmaceutical company’s stock worth $720,000 after buying an additional 174,333 shares during the period. 56.92% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company’s platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.